Key statistics
On Thursday, Lisata Therapeutics Inc (8NE:DUS) closed at 2.66, -20.36% below its 52-week high of 3.34, set on Jul 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.70 |
---|---|
High | 2.70 |
Low | 2.66 |
Bid | -- |
Offer | -- |
Previous close | 2.66 |
Average volume | 0.00 |
---|---|
Shares outstanding | 8.32m |
Free float | 6.73m |
P/E (TTM) | -- |
Market cap | 24.38m USD |
EPS (TTM) | -2.51 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 18:32 GMT.
More ▼
Announcements
- Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’
- Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
- Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
- Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
- Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
- Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
- Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
- Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
- Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
More ▼